Global Urological Cancer Market- Industry Analysis, Growth, Segmentation, Trends and Forecast 2020-2026

The Global Urological Cancer Market is anticipated to reach $xx MN in 2026 from $xx MN in 2020, by registering a CAGR of xx% during forecast period.

Market Overview & Dynamics:

Urologic cancers are caused by abnormal cell growth that occurs in the organs of the urinary tract, and the male reproductive tract. This may affect the tissues in bladder, kidney, prostate, penile and testicular. Most urologic cancers are treated with surgery, although other treatments are available for some conditions. Frequently, cancers in these organs produce symptoms such as pain, a lump, urinary tract infections (UTIs) or blood in the urine. Urological cancers are thought to account for 19.5% of global cancer prevalence.

Presence of hereditary cancer syndromes is the major driving factor

Family history and genetics, obesity, ageing population, increased usage of tobacco, smoking, herbal supplements containing aristolochic acid, contaminated water with arsenic, unhealthy diet, and lack of awareness about the poor genital hygiene are the major key drivers fuelling the market. Other factors such as new product innovation and research and development activities are likely to drive the market. Rising demand for hormonal therapies to treat cancer is also likely to boost the market. The report has profiled nineteen key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.

Segment Analysis:

The Global Urological Cancer is segmented on the basis of cancer type, treatment type and end-users.

Based on the cancer type, urological cancer is bifurcated into Prostate, bladder, kidney and testicular cancer. The prostate cancer segment is the most dominating segment due to its rising prevalence in North America. It is common among many men over age 50. Fortunately, most prostate cancer is detected early. On the basis of treatment type, it is divided into chemotherapy, hormonal therapy, and surgery and radiation therapy. The radiation therapy is most commonly used procedure for the treatment of urological cancer. Radiation therapy like CyberKnife is used in place or after the surgery. The CyberKnife — one of the most advanced forms of radiosurgery — is a painless, non-invasive treatment that delivers high doses of precisely targeted radiation to destroy tumors or lesions within the body. It uses a robotic arm to deliver highly focused beams of radiation. Global Urological Cancer Market To know about the Research Methodology :- Request Free Sample Report

Regional Insights:

Global Urological Cancer Market1

North America is expected to hold a dominant share of xx% during forecast period.

Rising prevalence of prostate cancer, which is common amongst men in US, contributes in the market growth. Prostate cancer affects every 1 in 7 men. In year 2020, it was estimated that 191,930 men in the United States will be diagnosed with prostate cancer. Around 60% of cases are diagnosed in men over 65 years of age. Second most prevalent cancer in US is Bladder Cancer. Europe is expected to hold the second largest share due to rising need for surgeries, rise in consumption of alcohol and smoking behaviour, advanced healthcare and rising awareness about urinary diseases. According to NHS, prostate cancer is the most common cancer among men in the U.K., with over 40,000 new cases diagnosed every year.

Asia Pacific is expected to become the fastest growing region during the forecast period at a CAGR of xx%.

Asia Pacific will command the global market owing to the drivers like improved medical infrastructure, increased healthcare expenditure, and medical tourism, presence of large target, increased awareness, and development of innovative and cost-effective solutions, improved standard of living and rise in disposable income. The market is anticipated to experience fast development in demand for treatment of Urological Cancer in emerging countries such as Japan, China, Brazil, India, Indonesia and South Korea over the forecast period. The report also helps in understanding Global Urological Cancer dynamics, structure by analyzing the market segments and project the Global Urological Cancer size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Urological Cancer make the report investor’s guide.

Scope of the report: Inquire before Buying

Global Urological Cancer Market2

By Region:

• North America • Europe • South America • MEA • APAC

Key Players:

• Pfizer Inc. • Novartis International AG • Johnson & Johnson Private Limited • Astellas Pharma Inc • AstraZeneca Plc. • GlaxoSmithKline plc • Sanofi S.A. • Celgene Corporation • Eli Lilly and Company • Bristol-Myers Squibb Company • F. Hoffmann-La Roche AG. • Kyowa Hakko Kirin Co., Ltd. • Boehringer Ingelheim GmbH • Ferring Pharmaceuticals • Dendreon Corporation • Abbott Laboratories • Roche Healthcare • Indevus Pharmaceuticals Inc • Ipsen
Global Urological Cancer Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: UROLOGICAL CANCER Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global UROLOGICAL CANCER Market Analysis and Forecast 6.1. UROLOGICAL CANCER Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global UROLOGICAL CANCER Market Analysis and Forecast, By Cancer Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 7.4. UROLOGICAL CANCER Market Size (US$ Mn) Forecast, By Cancer Type 7.5. UROLOGICAL CANCER Market Analysis, By Cancer Type 7.6. UROLOGICAL CANCER Market Attractiveness Analysis, By Cancer Type 8. Global UROLOGICAL CANCER Market Analysis and Forecast, By Treatment Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 8.4. UROLOGICAL CANCER Market Size (US$ Mn) Forecast, By Treatment Type 8.5. UROLOGICAL CANCER Market Analysis, By Treatment Type 8.6. UROLOGICAL CANCER Market Attractiveness Analysis, By Treatment Type 9. Global UROLOGICAL CANCER Market Analysis and Forecast By End-Users 9.1. Introduction and Definition 9.2. Key Findings 9.3. UROLOGICAL CANCER Market Value Share Analysis, By End-Users 9.4. UROLOGICAL CANCER Market Size (US$ Mn) Forecast, By End-Users 9.5. UROLOGICAL CANCER Market Analysis, By End-Users 9.6. UROLOGICAL CANCER Market Attractiveness Analysis, By End-Users 10. Global UROLOGICAL CANCER Market Analysis, By Region 10.1. UROLOGICAL CANCER Market Value Share Analysis, By Region 10.2. UROLOGICAL CANCER Market Size (US$ Mn) Forecast, By Region 10.3. UROLOGICAL CANCER Market Attractiveness Analysis, By Region 11. North America UROLOGICAL CANCER Market Analysis 11.1. Key Findings 11.2. North America UROLOGICAL CANCER Market Overview 11.3. North America UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 11.4. North America UROLOGICAL CANCER Market Forecast, By Cancer Type 11.4.1. Bladder cancer 11.4.2. Prostate cancer 11.4.3. Testicular cancer 11.4.4. Kidney cancer 11.5. North America UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 11.6. North America UROLOGICAL CANCER Market Forecast, By Treatment Type 11.6.1. Chemotherapy 11.6.2. Hormonal therapy 11.6.3. Surgery 11.6.4. Radiation therapy 11.7. North America UROLOGICAL CANCER Market Value Share Analysis, By End-Users 11.8. North America UROLOGICAL CANCER Market Forecast, By End-Users 11.8.1. Hospitals 11.8.2. Urological centers 11.8.3. Oncology centers 11.8.4. Specialty clinics 11.9. North America UROLOGICAL CANCER Market Value Share Analysis, By Country 11.10. North America UROLOGICAL CANCER Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America UROLOGICAL CANCER Market Analysis, By Country 11.12. U.S. UROLOGICAL CANCER Market Forecast, By Cancer Type 11.12.1. Bladder cancer 11.12.2. Prostate cancer 11.12.3. Testicular cancer 11.12.4. Kidney cancer 11.13. U.S. UROLOGICAL CANCER Market Forecast, By Treatment Type 11.13.1. Chemotherapy 11.13.2. Hormonal therapy 11.13.3. Surgery 11.13.4. Radiation therapy 11.14. U.S. UROLOGICAL CANCER Market Forecast, By End-Users 11.14.1. Hospitals 11.14.2. Urological centers 11.14.3. Oncology centers 11.14.4. Specialty clinics 11.15. Canada UROLOGICAL CANCER Market Forecast, By Cancer Type 11.15.1. Bladder cancer 11.15.2. Prostate cancer 11.15.3. Testicular cancer 11.15.4. Kidney cancer 11.16. Canada UROLOGICAL CANCER Market Forecast, By Treatment Type 11.16.1. Chemotherapy 11.16.2. Hormonal therapy 11.16.3. Surgery 11.16.4. Radiation therapy 11.17. Canada UROLOGICAL CANCER Market Forecast, By End-Users 11.17.1. Hospitals 11.17.2. Urological centers 11.17.3. Oncology centers 11.17.4. Specialty clinics 11.18. Mexico UROLOGICAL CANCER Market Forecast, By Cancer Type 11.18.1. Bladder cancer 11.18.2. Prostate cancer 11.18.3. Testicular cancer 11.18.4. Kidney cancer 11.19. Mexico UROLOGICAL CANCER Market Forecast, By Treatment Type 11.19.1. Chemotherapy 11.19.2. Hormonal therapy 11.19.3. Surgery 11.19.4. Radiation therapy 11.20. Mexico UROLOGICAL CANCER Market Forecast, By End-Users 11.20.1. Hospitals 11.20.2. Urological centers 11.20.3. Oncology centers 11.20.4. Specialty clinics 11.21. North America UROLOGICAL CANCER Market Attractiveness Analysis 11.21.1. By Cancer Type 11.21.2. By Treatment Type 11.21.3. By End-Users 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe UROLOGICAL CANCER Market Analysis 12.1. Key Findings 12.2. Europe UROLOGICAL CANCER Market Overview 12.3. Europe UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 12.4. Europe UROLOGICAL CANCER Market Forecast, By Cancer Type 12.4.1. Bladder cancer 12.4.2. Prostate cancer 12.4.3. Testicular cancer 12.4.4. Kidney cancer 12.5. Europe UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 12.6. Europe UROLOGICAL CANCER Market Forecast, By Treatment Type 12.6.1. Chemotherapy 12.6.2. Hormonal therapy 12.6.3. Surgery 12.6.4. Radiation therapy 12.7. Europe UROLOGICAL CANCER Market Value Share Analysis, By End-Users 12.8. Europe UROLOGICAL CANCER Market Forecast, By End-Users 12.8.1. Hospitals 12.8.2. Urological centers 12.8.3. Oncology centers 12.8.4. Specialty clinics 12.9. Europe UROLOGICAL CANCER Market Value Share Analysis, By Country 12.10. Europe UROLOGICAL CANCER Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany UROLOGICAL CANCER Market Forecast, By Cancer Type 12.11.1. Bladder cancer 12.11.2. Prostate cancer 12.11.3. Testicular cancer 12.11.4. Kidney cancer 12.12. Germany UROLOGICAL CANCER Market Forecast, By Treatment Type 12.12.1. Chemotherapy 12.12.2. Hormonal therapy 12.12.3. Surgery 12.12.4. Radiation therapy 12.13. Germany UROLOGICAL CANCER Market Forecast, By End-Users 12.13.1. Hospitals 12.13.2. Urological centers 12.13.3. Oncology centers 12.13.4. Specialty clinics 12.14. U.K. UROLOGICAL CANCER Market Forecast, By Cancer Type 12.14.1. Bladder cancer 12.14.2. Prostate cancer 12.14.3. Testicular cancer 12.14.4. Kidney cancer 12.15. U.K. UROLOGICAL CANCER Market Forecast, By Treatment Type 12.15.1. Chemotherapy 12.15.2. Hormonal therapy 12.15.3. Surgery 12.15.4. Radiation therapy 12.16. U.K. UROLOGICAL CANCER Market Forecast, By End-Users 12.16.1. Hospitals 12.16.2. Urological centers 12.16.3. Oncology centers 12.16.4. Specialty clinics 12.17. France UROLOGICAL CANCER Market Forecast, By Cancer Type 12.17.1. Bladder cancer 12.17.2. Prostate cancer 12.17.3. Testicular cancer 12.17.4. Kidney cancer 12.18. France UROLOGICAL CANCER Market Forecast, By Treatment Type 12.18.1. Chemotherapy 12.18.2. Hormonal therapy 12.18.3. Surgery 12.18.4. Radiation therapy 12.19. France UROLOGICAL CANCER Market Forecast, By End-Users 12.19.1. Hospitals 12.19.2. Urological centers 12.19.3. Oncology centers 12.19.4. Specialty clinics 12.20. Italy UROLOGICAL CANCER Market Forecast, By Cancer Type 12.20.1. Bladder cancer 12.20.2. Prostate cancer 12.20.3. Testicular cancer 12.20.4. Kidney cancer 12.21. Italy UROLOGICAL CANCER Market Forecast, By Treatment Type 12.21.1. Chemotherapy 12.21.2. Hormonal therapy 12.21.3. Surgery 12.21.4. Radiation therapy 12.22. Italy UROLOGICAL CANCER Market Forecast, By End-Users 12.22.1. Hospitals 12.22.2. Urological centers 12.22.3. Oncology centers 12.22.4. Specialty clinics 12.23. Spain UROLOGICAL CANCER Market Forecast, By Cancer Type 12.23.1. Bladder cancer 12.23.2. Prostate cancer 12.23.3. Testicular cancer 12.23.4. Kidney cancer 12.24. Spain UROLOGICAL CANCER Market Forecast, By Treatment Type 12.24.1. Chemotherapy 12.24.2. Hormonal therapy 12.24.3. Surgery 12.24.4. Radiation therapy 12.25. Spain UROLOGICAL CANCER Market Forecast, By End-Users 12.25.1. Hospitals 12.25.2. Urological centers 12.25.3. Oncology centers 12.25.4. Specialty clinics 12.26. Sweden UROLOGICAL CANCER Market Forecast, By Cancer Type 12.26.1. Bladder cancer 12.26.2. Prostate cancer 12.26.3. Testicular cancer 12.26.4. Kidney cancer 12.27. Sweden UROLOGICAL CANCER Market Forecast, By Treatment Type 12.27.1. Chemotherapy 12.27.2. Hormonal therapy 12.27.3. Surgery 12.27.4. Radiation therapy 12.28. Sweden UROLOGICAL CANCER Market Forecast, By End-Users 12.28.1. Hospitals 12.28.2. Urological centers 12.28.3. Oncology centers 12.28.4. Specialty clinics 12.29. CIS countries UROLOGICAL CANCER Market Forecast, By Cancer Type 12.29.1. Bladder cancer 12.29.2. Prostate cancer 12.29.3. Testicular cancer 12.29.4. Kidney cancer 12.30. CIS countries UROLOGICAL CANCER Market Forecast, By Treatment Type 12.30.1. Chemotherapy 12.30.2. Hormonal therapy 12.30.3. Surgery 12.30.4. Radiation therapy 12.31. CIS countries UROLOGICAL CANCER Market Forecast, By End-Users 12.31.1. Hospitals 12.31.2. Urological centers 12.31.3. Oncology centers 12.31.4. Specialty clinics 12.32. Rest of Europe UROLOGICAL CANCER Market Forecast, By Cancer Type 12.32.1. Bladder cancer 12.32.2. Prostate cancer 12.32.3. Testicular cancer 12.32.4. Kidney cancer 12.33. Rest of Europe UROLOGICAL CANCER Market Forecast, By Treatment Type 12.33.1. Chemotherapy 12.33.2. Hormonal therapy 12.33.3. Surgery 12.33.4. Radiation therapy 12.34. Rest of Europe UROLOGICAL CANCER Market Forecast, By End-Users 12.34.1. Hospitals 12.34.2. Urological centers 12.34.3. Oncology centers 12.34.4. Specialty clinics 12.35. Europe UROLOGICAL CANCER Market Attractiveness Analysis 12.35.1. By Treatment Type 12.35.2. By Cancer Type 12.35.3. By End-Users 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific UROLOGICAL CANCER Market Analysis 13.1. Key Findings 13.2. Asia Pacific UROLOGICAL CANCER Market Overview 13.3. Asia Pacific UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 13.4. Asia Pacific UROLOGICAL CANCER Market Forecast, By Cancer Type 13.4.1. Bladder cancer 13.4.2. Prostate cancer 13.4.3. Testicular cancer 13.4.4. Kidney cancer 13.5. Asia Pacific UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 13.6. Asia Pacific UROLOGICAL CANCER Market Forecast, By Treatment Type 13.6.1. Chemotherapy 13.6.2. Hormonal therapy 13.6.3. Surgery 13.6.4. Radiation therapy 13.7. Asia Pacific UROLOGICAL CANCER Market Value Share Analysis, By End-Users 13.8. Asia Pacific UROLOGICAL CANCER Market Forecast, By End-Users 13.8.1. Hospitals 13.8.2. Urological centers 13.8.3. Oncology centers 13.8.4. Specialty clinics 13.9. Asia Pacific UROLOGICAL CANCER Market Value Share Analysis, By Country 13.10. Asia Pacific UROLOGICAL CANCER Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific UROLOGICAL CANCER Market Analysis, By Country 13.12. China UROLOGICAL CANCER Market Forecast, By Cancer Type 13.12.1. Bladder cancer 13.12.2. Prostate cancer 13.12.3. Testicular cancer 13.12.4. Kidney cancer 13.13. China UROLOGICAL CANCER Market Forecast, By Treatment Type 13.13.1. Chemotherapy 13.13.2. Hormonal therapy 13.13.3. Surgery 13.13.4. Radiation therapy 13.14. China UROLOGICAL CANCER Market Forecast, By End-Users 13.14.1. Hospitals 13.14.2. Urological centers 13.14.3. Oncology centers 13.14.4. Specialty clinics 13.15. India UROLOGICAL CANCER Market Forecast, By Cancer Type 13.15.1. Bladder cancer 13.15.2. Prostate cancer 13.15.3. Testicular cancer 13.15.4. Kidney cancer 13.16. India UROLOGICAL CANCER Market Forecast, By Treatment Type 13.16.1. Chemotherapy 13.16.2. Hormonal therapy 13.16.3. Surgery 13.16.4. Radiation therapy 13.17. India UROLOGICAL CANCER Market Forecast, By End-Users 13.17.1. Hospitals 13.17.2. Urological centers 13.17.3. Oncology centers 13.17.4. Specialty clinics 13.18. Japan UROLOGICAL CANCER Market Forecast, By Cancer Type 13.18.1. Bladder cancer 13.18.2. Prostate cancer 13.18.3. Testicular cancer 13.18.4. Kidney cancer 13.19. Japan UROLOGICAL CANCER Market Forecast, By Treatment Type 13.19.1. Chemotherapy 13.19.2. Hormonal therapy 13.19.3. Surgery 13.19.4. Radiation therapy 13.20. Japan UROLOGICAL CANCER Market Forecast, By End-Users 13.20.1. Hospitals 13.20.2. Urological centers 13.20.3. Oncology centers 13.20.4. Specialty clinics 13.21. South Korea UROLOGICAL CANCER Market Forecast, By Cancer Type 13.21.1. Bladder cancer 13.21.2. Prostate cancer 13.21.3. Testicular cancer 13.21.4. Kidney cancer 13.22. South Korea UROLOGICAL CANCER Market Forecast, By Treatment Type 13.22.1. Chemotherapy 13.22.2. Hormonal therapy 13.22.3. Surgery 13.22.4. Radiation therapy 13.23. South Korea UROLOGICAL CANCER Market Forecast, By End-Users 13.23.1. Hospitals 13.23.2. Urological centers 13.23.3. Oncology centers 13.23.4. Specialty clinics 13.24. Australia UROLOGICAL CANCER Market Forecast, By Cancer Type 13.24.1. Bladder cancer 13.24.2. Prostate cancer 13.24.3. Testicular cancer 13.24.4. Kidney cancer 13.25. Australia UROLOGICAL CANCER Market Forecast, By Treatment Type 13.25.1. Chemotherapy 13.25.2. Hormonal therapy 13.25.3. Surgery 13.25.4. Radiation therapy 13.26. Australia UROLOGICAL CANCER Market Forecast, By End-Users 13.26.1. Hospitals 13.26.2. Urological centers 13.26.3. Oncology centers 13.26.4. Specialty clinics 13.27. ASEAN UROLOGICAL CANCER Market Forecast, By Cancer Type 13.27.1. Bladder cancer 13.27.2. Prostate cancer 13.27.3. Testicular cancer 13.27.4. Kidney cancer 13.28. ASEAN UROLOGICAL CANCER Market Forecast, By Treatment Type 13.28.1. Chemotherapy 13.28.2. Hormonal therapy 13.28.3. Surgery 13.28.4. Radiation therapy 13.29. ASEAN UROLOGICAL CANCER Market Forecast, By End-Users 13.29.1. Hospitals 13.29.2. Urological centers 13.29.3. Oncology centers 13.29.4. Specialty clinics 13.30. Rest of Asia Pacific UROLOGICAL CANCER Market Forecast, By Cancer Type 13.30.1. Bladder cancer 13.30.2. Prostate cancer 13.30.3. Testicular cancer 13.30.4. Kidney cancer 13.31. Rest of Asia Pacific UROLOGICAL CANCER Market Forecast, By Treatment Type 13.31.1. Chemotherapy 13.31.2. Hormonal therapy 13.31.3. Surgery 13.31.4. Radiation therapy 13.32. Rest of Asia Pacific UROLOGICAL CANCER Market Forecast, By End-Users 13.32.1. Hospitals 13.32.2. Urological centers 13.32.3. Oncology centers 13.32.4. Specialty clinics 13.33. Asia Pacific UROLOGICAL CANCER Market Attractiveness Analysis 13.33.1. By Cancer Type 13.33.2. By Treatment Type 13.33.3. By End-Users 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa UROLOGICAL CANCER Market Analysis 14.1. Key Findings 14.2. Middle East & Africa UROLOGICAL CANCER Market Overview 14.3. Middle East & Africa UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 14.4. Middle East & Africa UROLOGICAL CANCER Market Forecast, By Cancer Type 14.4.1. Bladder cancer 14.4.2. Prostate cancer 14.4.3. Testicular cancer 14.4.4. Kidney cancer 14.5. Middle East & Africa UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 14.6. Middle East & Africa UROLOGICAL CANCER Market Forecast, By Treatment Type 14.6.1. Chemotherapy 14.6.2. Hormonal therapy 14.6.3. Surgery 14.6.4. Radiation therapy 14.7. Middle East & Africa UROLOGICAL CANCER Market Value Share Analysis, By End-Users 14.8. Middle East & Africa UROLOGICAL CANCER Market Forecast, By End-Users 14.8.1. Hospitals 14.8.2. Urological centers 14.8.3. Oncology centers 14.8.4. Specialty clinics 14.9. Middle East & Africa UROLOGICAL CANCER Market Value Share Analysis, By Country 14.10. Middle East & Africa UROLOGICAL CANCER Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa UROLOGICAL CANCER Market Analysis, By Country 14.12. GCC Countries UROLOGICAL CANCER Market Forecast, By Cancer Type 14.12.1. Bladder cancer 14.12.2. Prostate cancer 14.12.3. Testicular cancer 14.12.4. Kidney cancer 14.13. GCC Countries UROLOGICAL CANCER Market Forecast, By Treatment Type 14.13.1. Chemotherapy 14.13.2. Hormonal therapy 14.13.3. Surgery 14.13.4. Radiation therapy 14.14. GCC Countries UROLOGICAL CANCER Market Forecast, By End-Users 14.14.1. Hospitals 14.14.2. Urological centers 14.14.3. Oncology centers 14.14.4. Specialty clinics 14.15. South Africa UROLOGICAL CANCER Market Forecast, By Cancer Type 14.15.1. Bladder cancer 14.15.2. Prostate cancer 14.15.3. Testicular cancer 14.15.4. Kidney cancer 14.16. South Africa UROLOGICAL CANCER Market Forecast, By Treatment Type 14.16.1. Chemotherapy 14.16.2. Hormonal therapy 14.16.3. Surgery 14.16.4. Radiation therapy 14.17. South Africa UROLOGICAL CANCER Market Forecast, By End-Users 14.17.1. Hospitals 14.17.2. Urological centers 14.17.3. Oncology centers 14.17.4. Specialty clinics 14.18. Nigeria UROLOGICAL CANCER Market Forecast, By Cancer Type 14.18.1. Bladder cancer 14.18.2. Prostate cancer 14.18.3. Testicular cancer 14.18.4. Kidney cancer 14.19. Nigeria UROLOGICAL CANCER Market Forecast, By Treatment Type 14.19.1. Chemotherapy 14.19.2. Hormonal therapy 14.19.3. Surgery 14.19.4. Radiation therapy 14.20. Nigeria UROLOGICAL CANCER Market Forecast, By End-Users 14.20.1. Hospitals 14.20.2. Urological centers 14.20.3. Oncology centers 14.20.4. Specialty clinics 14.21. Egypt UROLOGICAL CANCER Market Forecast, By Cancer Type 14.21.1. Bladder cancer 14.21.2. Prostate cancer 14.21.3. Testicular cancer 14.21.4. Kidney cancer 14.22. Egypt UROLOGICAL CANCER Market Forecast, By Treatment Type 14.22.1. Chemotherapy 14.22.2. Hormonal therapy 14.22.3. Surgery 14.22.4. Radiation therapy 14.23. Egypt UROLOGICAL CANCER Market Forecast, By End-Users 14.23.1. Hospitals 14.23.2. Urological centers 14.23.3. Oncology centers 14.23.4. Specialty clinics 14.24. Rest of Middle East & Africa UROLOGICAL CANCER Market Forecast, By Cancer Type 14.24.1. Bladder cancer 14.24.2. Prostate cancer 14.24.3. Testicular cancer 14.24.4. Kidney cancer 14.25. Rest of Middle East & Africa UROLOGICAL CANCER Market Forecast, By Treatment Type 14.25.1. Chemotherapy 14.25.2. Hormonal therapy 14.25.3. Surgery 14.25.4. Radiation therapy 14.26. Rest of Middle East & Africa UROLOGICAL CANCER Market Forecast, By End-Users 14.26.1. Hospitals 14.26.2. Urological centers 14.26.3. Oncology centers 14.26.4. Specialty clinics 14.27. Middle East & Africa UROLOGICAL CANCER Market Attractiveness Analysis 14.27.1. By Cancer Type 14.27.2. By Treatment Type 14.27.3. By End-Users 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America UROLOGICAL CANCER Market Analysis 15.1. Key Findings 15.2. South America UROLOGICAL CANCER Market Overview 15.3. South America UROLOGICAL CANCER Market Value Share Analysis, By Cancer Type 15.4. South America UROLOGICAL CANCER Market Forecast, By Cancer Type 15.4.1. Bladder cancer 15.4.2. Prostate cancer 15.4.3. Testicular cancer 15.4.4. Kidney cancer 15.5. South America UROLOGICAL CANCER Market Value Share Analysis, By Treatment Type 15.6. South America UROLOGICAL CANCER Market Forecast, By Treatment Type 15.6.1. Chemotherapy 15.6.2. Hormonal therapy 15.6.3. Surgery 15.6.4. Radiation therapy 15.7. South America UROLOGICAL CANCER Market Value Share Analysis, By End-Users 15.8. South America UROLOGICAL CANCER Market Forecast, By End-Users 15.8.1. Hospitals 15.8.2. Urological centers 15.8.3. Oncology centers 15.8.4. Specialty clinics 15.9. South America UROLOGICAL CANCER Market Value Share Analysis, By Country 15.10. South America UROLOGICAL CANCER Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America UROLOGICAL CANCER Market Analysis, By Country 15.12. Brazil UROLOGICAL CANCER Market Forecast, By Cancer Type 15.12.1. Bladder cancer 15.12.2. Prostate cancer 15.12.3. Testicular cancer 15.12.4. Kidney cancer 15.13. Brazil UROLOGICAL CANCER Market Forecast, By Treatment Type 15.13.1. Chemotherapy 15.13.2. Hormonal therapy 15.13.3. Surgery 15.13.4. Radiation therapy 15.14. Brazil UROLOGICAL CANCER Market Forecast, By End-Users 15.14.1. Hospitals 15.14.2. Urological centers 15.14.3. Oncology centers 15.14.4. Specialty clinics 15.15. Colombia UROLOGICAL CANCER Market Forecast, By Cancer Type 15.15.1. Bladder cancer 15.15.2. Prostate cancer 15.15.3. Testicular cancer 15.15.4. Kidney cancer 15.16. Colombia UROLOGICAL CANCER Market Forecast, By Treatment Type 15.16.1. Chemotherapy 15.16.2. Hormonal therapy 15.16.3. Surgery 15.16.4. Radiation therapy 15.17. Colombia UROLOGICAL CANCER Market Forecast, By End-Users 15.17.1. Hospitals 15.17.2. Urological centers 15.17.3. Oncology centers 15.17.4. Specialty clinics 15.18. Argentina UROLOGICAL CANCER Market Forecast, By Cancer Type 15.18.1. Bladder cancer 15.18.2. Prostate cancer 15.18.3. Testicular cancer 15.18.4. Kidney cancer 15.19. Argentina UROLOGICAL CANCER Market Forecast, By Treatment Type 15.19.1. Chemotherapy 15.19.2. Hormonal therapy 15.19.3. Surgery 15.19.4. Radiation therapy 15.20. Argentina UROLOGICAL CANCER Market Forecast, By End-Users 15.20.1. Hospitals 15.20.2. Urological centers 15.20.3. Oncology centers 15.20.4. Specialty clinics 15.21. Rest of South America UROLOGICAL CANCER Market Forecast, By Cancer Type 15.21.1. Bladder cancer 15.21.2. Prostate cancer 15.21.3. Testicular cancer 15.21.4. Kidney cancer 15.22. Rest of South America UROLOGICAL CANCER Market Forecast, By Treatment Type 15.22.1. Chemotherapy 15.22.2. Hormonal therapy 15.22.3. Surgery 15.22.4. Radiation therapy 15.23. Rest of South America UROLOGICAL CANCER Market Forecast, By End-Users 15.23.1. Hospitals 15.23.2. Urological centers 15.23.3. Oncology centers 15.23.4. Specialty clinics 15.24. South America UROLOGICAL CANCER Market Attractiveness Analysis 15.24.1. By Cancer Type 15.24.2. By Treatment Type 15.24.3. By End-Users 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Component 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Novartis International AG 16.3.3. Johnson & Johnson Private Limited 16.3.4. Astellas Pharma Inc 16.3.5. AstraZeneca Plc. 16.3.6. GlaxoSmithKline plc 16.3.7. Sanofi S.A. 16.3.8. Celgene Corporation 16.3.9. Eli Lilly and Company 16.3.10. Bristol-Myers Squibb Company 16.3.11. F. Hoffmann-La Roche AG. 16.3.12. Kyowa Hakko Kirin Co., Ltd. 16.3.13. Boehringer Ingelheim GmbH 16.3.14. Ferring Pharmaceuticals 16.3.15. Dendreon Corporation 16.3.16. Abbott Laboratories 16.3.17. Roche Healthcare 16.3.18. Indevus Pharmaceuticals Inc 16.3.19. Ipsen 17. Primary key Insights

About This Report

Report ID 85866
Category Healthcare
Published Date March 2021
Updated Date
Contact Us